<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="[2], grid.410382.c0000 0004 0415 5210Florida Department of Health, Division of" exact="Disease" post="Control and Health Protection, Bureau of Communicable Diseases, HIV/AIDS"/>
 <result pre="of Disease Control and Health Protection, Bureau of Communicable Diseases," exact="HIV/AIDS" post="Section, [3], grid.416738.f0000 0001 2163 0069Centers for Disease Control"/>
 <result pre="Communicable Diseases, HIV/AIDS Section, [3], grid.416738.f0000 0001 2163 0069Centers for" exact="Disease" post="Control and Prevention, National Center for HIV/AIDS, Viral Hepatitis,"/>
 <result pre="0069Centers for Disease Control and Prevention, National Center for HIV/AIDS," exact="Viral" post="Hepatitis, STD and TB Prevention, Division of STD Prevention,"/>
 <result pre="Division of STD Prevention, [4], grid.416738.f0000 0001 2163 0069Centers for" exact="Disease" post="Control and Prevention, National Center for HIV/AIDS, Viral Hepatitis,"/>
 <result pre="0069Centers for Disease Control and Prevention, National Center for HIV/AIDS," exact="Viral" post="Hepatitis, STD and TB Prevention, Division of HIV/AIDS Prevention,"/>
 <result pre="for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Division of" exact="HIV/AIDS" post="Prevention, epub: 2019-9-9pmc-release: 2019-9-9ppub: 2020241246256(C) , Open AccessThis article"/>
 <result pre="Department of Health to conduct an epidemiologic investigation. All seven" exact="acute" post="HIV seroconversions were linked to care (86% within 30Â"/>
 <result pre="were linked to care (86% within 30Â days) and achieved" exact="viral" post="suppression (mean 70Â days). Six of the seven individuals"/>
 <result pre="and patient navigation, could be an effective model for achieving" exact="viral" post="suppression for people who inject drugs. Resumen La prevenciÃ³n"/>
 <result pre="people who inject drugs. Resumen La prevenciÃ³n de brotes de" exact="VIH" post="entre las personas que se inyectan drogas sigue siendo"/>
 <result pre="siendo un desafÃ­o para poner fin a la epidemia de" exact="VIH" post="en los Estados Unidos. El primer programa legal de"/>
 <result pre="Salud para realizar una investigaciÃ³n epidemiolÃ³gica. Siete seroconversiones agudas de" exact="VIH" post="fueron identificadas y se vincularon a la atenciÃ³n mÃ©dica"/>
 <result pre="atenciÃ³n mÃ©dica (86% en 30 dÃ­as) y lograron la supresiÃ³n" exact="viral" post="(media 70 dÃ­as). Seis de los siete individuos estÃ¡n"/>
 <result pre="menos otras dos seroconversiones. El anÃ¡lisis de los genotipos del" exact="VIH" post="revelÃ³ que dos individuos estÃ¡n conectados molecularmente a una"/>
 <result pre="paciente, podrÃ­a ser un modelo eficaz para lograr la supresiÃ³n" exact="viral" post="de las personas que se inyectan drogas. Keywords People"/>
 <result pre="are injectable, promoting conditions that expedite the rapid transmission of" exact="communicable diseases," post="including HIV and hepatitis C (HCV), and exacerbating these"/>
 <result pre="expedite the rapid transmission of communicable diseases, including HIV and" exact="hepatitis C" post="(HCV), and exacerbating these serious public health epidemics as"/>
 <result pre="Additionally, challenges in linkage to care, retention in care, and" exact="viral" post="suppression in high risk people who inject drugs (PWID)"/>
 <result pre="and participation in transactional sex are typically affiliated with PWID," exact="disease" post="transmission is compounded among such high-risk individuals [5, 6]."/>
 <result pre="individuals [5, 6]. Evidence-based public health interventions can help mitigate" exact="disease" post="transmission in these vulnerable populations. Yet, absence of interventions"/>
 <result pre="can help mitigate disease transmission in these vulnerable populations. Yet," exact="absence of" post="interventions and delays in public health action have been"/>
 <result pre="venues for syringe disposal, the Florida legislature passed the 2016" exact="Infectious" post="Disease Elimination Act (IDEA), authorizing the stateâ€™s first SSP"/>
 <result pre="for syringe disposal, the Florida legislature passed the 2016 Infectious" exact="Disease" post="Elimination Act (IDEA), authorizing the stateâ€™s first SSP at"/>
 <result pre="at the University of Miami [13], [14]. The program is" exact="limited" post="to one-to-one syringe exchange by statute but also offers"/>
 <result pre="and treatment. DOH initiated an epidemiologic investigation and embedded a" exact="Disease" post="Intervention Specialist (DIS) within the SSP to facilitate contact"/>
 <result pre="been conducted, leading to an understanding of causal pathways and" exact="disease" post="transmission [17, 19]. A multidisciplinary investigation between the IDEA"/>
 <result pre="SSP, local and state health departments, and the Centers for" exact="Disease" post="Control and Prevention (CDC) was launched in order to"/>
 <result pre="case definition for a reportable HIV case [20]. Furthermore, a" exact="primary" post="epidemiologic link was defined as a sexual, syringe or"/>
 <result pre="embedded at the SSP for contact tracing and partner elicitation." exact="Blood" post="specimens for individuals with confirmed seroconversion were obtained, tested,"/>
 <result pre="and screening of persons for HIV, syphilis, gonorrhea, chlamydia, and" exact="hepatitis" post="B and C. Laboratory Testing Individuals were screened for"/>
 <result pre="hepatitis B and C. Laboratory Testing Individuals were screened for" exact="HIV infection" post="using a point-of-care rapid HIV test (OraQuick ADVANCEÂ® Rapid"/>
 <result pre="B and C. Laboratory Testing Individuals were screened for HIV" exact="infection" post="using a point-of-care rapid HIV test (OraQuick ADVANCEÂ® Rapid"/>
 <result pre="using a point-of-care rapid HIV test (OraQuick ADVANCEÂ® Rapid HIV-1/2" exact="Antibody" post="Test, OraSure Technologies). Individuals with reactive rapid tests received"/>
 <result pre="type-differentiating immunoassay). Other clinical labs including HIV-1 RNA/DNA NAAT (quantitative" exact="viral" post="load), HIV-1 Genotype (protease/reverse transcriptase nucleotide sequence), and CD4"/>
 <result pre="supply of BIC/FTC/TAF and had up to 60Â days to" exact="complete" post="financial eligibility and enrollment into the AIDS Drug Assistance"/>
 <result pre="DOH surveillance systems for HIV reporting and case management (enhanced" exact="HIV/AIDS" post="Reporting System and Patient Reporting Investigation Surveillance Manager [PRISM])."/>
 <result pre="Investigation Surveillance Manager [PRISM]). Clinical characteristics and outcomes including baseline" exact="viral" post="load and CD4 count, time to linkage to care,"/>
 <result pre="and CD4 count, time to linkage to care, time to" exact="viral" post="suppression, and coinfection or prior infection with syphilis and"/>
 <result pre="to care, time to viral suppression, and coinfection or prior" exact="infection" post="with syphilis and HCV were obtained for all linked"/>
 <result pre="time to viral suppression, and coinfection or prior infection with" exact="syphilis" post="and HCV were obtained for all linked individuals. Time"/>
 <result pre="first visit to an HIV clinic with a reported initial" exact="viral" post="load. Time to viral suppression was defined as the"/>
 <result pre="HIV clinic with a reported initial viral load. Time to" exact="viral" post="suppression was defined as the total number of days"/>
 <result pre="viral load. Time to viral suppression was defined as the" exact="total" post="number of days between anonymous reactive rapid HIV test"/>
 <result pre="SSP and the specimen collection date for the first reported" exact="viral" post="load of less than 200 copies/mL. In-care time to"/>
 <result pre="viral load of less than 200 copies/mL. In-care time to" exact="viral" post="suppression was defined as the number of days between"/>
 <result pre="the number of days between the date of first reported" exact="viral" post="load and the first reported viral load of less"/>
 <result pre="date of first reported viral load and the first reported" exact="viral" post="load of less than 200 copies/mL. HIV diagnosis date"/>
 <result pre="with an HIV diagnosis met the case definition of an" exact="acute" post="HIV seroconversion. The other three suspected cases had been"/>
 <result pre="also reviewed for molecular linkages, seven of whom were also" exact="primary" post="epidemiologic links to a confirmed case. An embedded DIS"/>
 <result pre="to locate for investigation. Confirmed cases had a median baseline" exact="viral" post="load of 173,691 copies per mL (range 477â€&quot;684,490) and"/>
 <result pre="syringe services program, Miami, FL, 2018 Individuals with HIV seroconversion(nâ€‰=â€‰7)" exact="Primary" post="epidemiologic linksa(nâ€‰=â€‰10) IDEA participants living with HIVa(nâ€‰=â€‰32) Demographics Ageâ€&quot;median(range)"/>
 <result pre="Sexâ€&quot;n(%) Â Male 6 (85.7) 4 (40.0) 17 (53.1) Â" exact="Female" post="1 (14.3) 6 (60.0) 15 (46.9) Race/ethnicityâ€&quot;n(%) Â non-Hispanic"/>
 <result pre="2 (28.6) 2 (20.0) 2 (6.3) HIV clinical characteristics Baseline" exact="viral" post="load (copies/mL)â€&quot;median(range) 173,691 (477â€&quot;684,490) 37,473 ( 13,207 ( Baseline"/>
 <result pre="linkage to careâ€&quot;mean days(range) 20 (0â€&quot;49) â€&quot; â€&quot; Time to" exact="viral" post="suppressionâ€&quot;mean(range) 70 (14â€&quot;158) â€&quot; â€&quot; Time to in-care viral"/>
 <result pre="to viral suppressionâ€&quot;mean(range) 70 (14â€&quot;158) â€&quot; â€&quot; Time to in-care" exact="viral" post="suppressionâ€&quot;mean days(range) 50 (14â€&quot;125) 39 (0â€&quot;96) 874 (0â€&quot;6168) HIV"/>
 <result pre="18 (56.3) Â No 2 (28.6) 5 (62.5) 14 (43.7)" exact="Hepatitis" post="C antibodydâ€&quot;n(%) Â Positive before 2018 4 (57.1) 5"/>
 <result pre="7 (21.9) Â Unknown 3 (42.9) 1 (1.3) 11 (34.4)" exact="Hepatitis" post="C NATdâ€&quot;n(%) Â Positive before 2018 1 (14.3) 3"/>
 <result pre="individuals are represented in both groups bTwo individuals from the" exact="primary" post="epidemiologic links category were excluded from the self-reported HIV"/>
 <result pre="seven individuals with seroconversion were linked to care and achieved" exact="viral" post="suppression with a mean time of 70 (14â€&quot;158) days"/>
 <result pre="to care was 20 (0â€&quot;49) days and time to in-care" exact="viral" post="suppression was 50 (14â€&quot;125) days. Only 53% (17 of"/>
 <result pre="32) of the SSP participants with previously diagnosed HIV achieved" exact="viral" post="suppression by the end of the investigation period. Fig.Â"/>
 <result pre="rapid antibody test at IDEA SSP. Blue dots represent documented" exact="viral" post="load suppression ( Transmission Network Dynamics Of the seven"/>
 <result pre="sexual contact. Two individuals with seroconversion and five individuals with" exact="primary" post="epi-links self-reported exchanging sex for money or drugs. Resistance"/>
 <result pre="with primary epi-links self-reported exchanging sex for money or drugs." exact="Resistance" post="interpretations to HIV-1 antiretrovirals were obtained for all seven"/>
 <result pre="through Secure HIV TRACE for molecular linkage analysis. Fig.Â 2" exact="Primary" post="epidemiologic and molecular network of individuals with confirmed HIV"/>
 <result pre="or works (injection equipment) sharing connections between individuals in the" exact="primary" post="network. Social links include social connections that do not"/>
 <result pre="sexual, needle or works sharing relationships between individuals in the" exact="primary" post="network Analysis of the five HIV genotypes revealed that"/>
 <result pre="and 7) at the 0.5% genetic distance. Outside of the" exact="primary" post="epi-linked network, two additional persons with diagnosed HIV (cases"/>
 <result pre="epidemiological or social linkages to individuals in the risk network." exact="Resistance" post="interpretation patterns and specific virus mutations for 13 of"/>
 <result pre="Two individuals with seroconversion (case 6 and 7) and one" exact="primary" post="epi-linkage (case 13) linked molecularly at the 0.5% genetic"/>
 <result pre="Genetic mutations of individuals with confirmed HIV seroconversion and associated" exact="primary" post="epidemiologic and molecular linkages, Miami, FL, 2018 ID Year"/>
 <result pre="epidemiological practices or molecular analyses alone as each source was" exact="incomplete" post="in defining relationships within the network. This is in"/>
 <result pre="support the building of recent and rapid transmission networks for" exact="acute" post="HIV infection. In Miami, response efforts were coordinated in"/>
 <result pre="the building of recent and rapid transmission networks for acute" exact="HIV infection." post="In Miami, response efforts were coordinated in collaboration between"/>
 <result pre="diagnosis and immediate ART initiation was prioritized to rapidly decrease" exact="viral" post="transmission, reduce the impact of a potential outbreak, and"/>
 <result pre="in Miami [32, 33]. The high linkage to care and" exact="viral" post="suppression rates among the seven individuals with seroconversion were"/>
 <result pre="by PWID and allowed SSP patients to achieve rapid in-care" exact="viral" post="suppression. However, PWID with previously diagnosed HIV may require"/>
 <result pre="Medication management at the SSP likely also contributed to rapid" exact="viral" post="suppression in patients with acute HIV. SSP staff obtained"/>
 <result pre="likely also contributed to rapid viral suppression in patients with" exact="acute" post="HIV. SSP staff obtained third party authorization to pick"/>
 <result pre="psychosocial counseling was central to increased initiation of ART and" exact="viral" post="suppression as well as decreased transmission among PWID [35]."/>
 <result pre="for a challenging patient population in a complex healthcare system." exact="Increased" post="availability of syringes through outreach trips to the geographic"/>
 <result pre="eligible, the AIDS Drug Assistance Program (ADAP) will follow the" exact="American" post="Association for the Study of Liver Diseases (AASLD) Guidelines"/>
 <result pre="(ADAP) will follow the American Association for the Study of" exact="Liver Diseases" post="(AASLD) Guidelines for HCV treatment for those co-infected with"/>
 <result pre="will follow the American Association for the Study of Liver" exact="Diseases" post="(AASLD) Guidelines for HCV treatment for those co-infected with"/>
 <result pre="knowledge this is the first study to show such rapid" exact="viral" post="suppression in PWID by introducing an expanded and integrated"/>
 <result pre="to bring timely and appropriate linkage to medical care and" exact="disease" post="intervention. In Miami, the early diagnosis, linkage to care,"/>
 <result pre="intervention. In Miami, the early diagnosis, linkage to care, and" exact="viral" post="suppression potentially averted new HIV transmissions in this network"/>
 <result pre="model for identifying new transmissions, engaging individuals into care, achieving" exact="viral" post="suppression in PWID, and working towards overall community harm"/>
 <result pre="not necessarily reflect the official position of the Centers for" exact="Disease" post="Control and Prevention or the authorsâ€™ affiliated institutions. Publisher's"/>
 <result pre="transmission network. The scholarly work was funded by Sylvester Comprehensive" exact="Cancer" post="Center at the University of Miami. References References 1.Des"/>
 <result pre="Center at the University of Miami. References References 1.Des JarlaisDCKerrTCarrieriPFeelemyerJArastehKHIV" exact="infection" post="among persons who inject drugs: ending old epidemics and"/>
 <result pre="need cultural anthropologists in the South BronxDialect Anthropol201640439541010.1007/s10624-016-9443-427917016 3.Karch D." exact="HIV infection" post="care and viral suppression among people who inject drugs,"/>
 <result pre="cultural anthropologists in the South BronxDialect Anthropol201640439541010.1007/s10624-016-9443-427917016 3.Karch D. HIV" exact="infection" post="care and viral suppression among people who inject drugs,"/>
 <result pre="the South BronxDialect Anthropol201640439541010.1007/s10624-016-9443-427917016 3.Karch D. HIV infection care and" exact="viral" post="suppression among people who inject drugs, 28 US Jurisdictions,"/>
 <result pre="inject drugs, 28 US Jurisdictions, 2012â€&quot;2013. 2019. 4.KimNWeltySRezaTSearsDMcFarlandWRaymondHFUndiagnosed and untreated" exact="HIV infection" post="among persons who inject drugs: results of three national"/>
 <result pre="drugs, 28 US Jurisdictions, 2012â€&quot;2013. 2019. 4.KimNWeltySRezaTSearsDMcFarlandWRaymondHFUndiagnosed and untreated HIV" exact="infection" post="among persons who inject drugs: results of three national"/>
 <result pre="meta-analysisInt J Epidemiol201443123524810.1093/ije/dyt24324374889 9.MacArthurGJvan VelzenEPalmateerNKimberJPharrisAHopeVet al.Interventions to prevent HIV and" exact="Hepatitis" post="C in people who inject drugs: a review of"/>
 <result pre="evidence of effectivenessInt J Drug Policy2014251345210.1016/j.drugpo.2013.07.00123973009 10.ChoopanyaKMartinMSuntharasamaiPSangkumUMockPALeethochawalitMet al.Antiretroviral prophylaxis for" exact="HIV infection" post="in injecting drug users in Bangkok, Thailand (the Bangkok"/>
 <result pre="of effectivenessInt J Drug Policy2014251345210.1016/j.drugpo.2013.07.00123973009 10.ChoopanyaKMartinMSuntharasamaiPSangkumUMockPALeethochawalitMet al.Antiretroviral prophylaxis for HIV" exact="infection" post="in injecting drug users in Bangkok, Thailand (the Bangkok"/>
 <result pre="Surveillance Report; 2017. 29. 13.TookesHEDiazCLiHKhalidRDoblecki-LewisSA cost analysis of hospitalizations for" exact="infections" post="related to injection drug use at a county safety-net"/>
 <result pre="of HIV-1 transmission in New York CityPLoS Pathog2017131e100600010.1371/journal.ppat.100600028068413 18.PetersPJPontonesPHooverKWPatelMRGalangRRShieldsJet al.HIV" exact="infection" post="linked to injection use of oxymorphone in Indiana, 2014â€&quot;2015N"/>
 <result pre="al.Detailed transmission network analysis of a large opiate-driven outbreak of" exact="HIV infection" post="in the United StatesJ Infect Dis201721691053106210.1093/infdis/jix30729029156 25.DeckerMRWirtzALBaralSDPeryshkinaAMogilnyiVWeberRAet al.Injection drug"/>
 <result pre="transmission network analysis of a large opiate-driven outbreak of HIV" exact="infection" post="in the United StatesJ Infect Dis201721691053106210.1093/infdis/jix30729029156 25.DeckerMRWirtzALBaralSDPeryshkinaAMogilnyiVWeberRAet al.Injection drug"/>
 <result pre="al.Injection drug use, sexual risk, violence and STI/HIV among Moscow" exact="female" post="sex workersSex Transm Infect.201288427828310.1136/sextrans-2011-05017122287530 26.BaconOLumPHahnJEvansJDavidsonPMossAet al.Commercial sex work and"/>
 <result pre="workersSex Transm Infect.201288427828310.1136/sextrans-2011-05017122287530 26.BaconOLumPHahnJEvansJDavidsonPMossAet al.Commercial sex work and risk of" exact="HIV infection" post="among young drug-injecting men who have sex with men"/>
 <result pre="Transm Infect.201288427828310.1136/sextrans-2011-05017122287530 26.BaconOLumPHahnJEvansJDavidsonPMossAet al.Commercial sex work and risk of HIV" exact="infection" post="among young drug-injecting men who have sex with men"/>
 <result pre="accumulating drug resistance mutations in the HIV genomeValue Health200710320421310.1111/j.1524-4733.2007.00170.x17532813 28.BernardinFKongDPeddadaLBaxter-LoweLADelwartEHuman" exact="immunodeficiency" post="virus mutations during the 1st month of infection are"/>
 <result pre="Health200710320421310.1111/j.1524-4733.2007.00170.x17532813 28.BernardinFKongDPeddadaLBaxter-LoweLADelwartEHuman immunodeficiency virus mutations during the 1st month of" exact="infection" post="are preferentially found in known cytotoxic T-lymphocyte epitopesJ Virol20057917115231152810.1128/JVI.79.17.11523-11528.200516103205"/>
 <result pre="in known cytotoxic T-lymphocyte epitopesJ Virol20057917115231152810.1128/JVI.79.17.11523-11528.200516103205 29.CohenMSChenYQMcCauleyMGambleTHosseinipourMCKumarasamyNet al.Prevention of HIV-1" exact="infection" post="with early antiretroviral therapyN Engl J Med2011365649350510.1056/NEJMoa110524321767103 30.DieffenbachCWFauciASUniversal voluntary"/>
 <result pre="effect of same-day observed initiation of antiretroviral therapy on HIV" exact="viral" post="load and treatment outcomes in a US public health"/>
 <result pre="entry program in the South: improving access to care and" exact="viral" post="suppression. Conference on Retroviruses and Opportunistic Infections; Boston, MA;"/>
 <result pre="feasibility and efficacy studyLancet20183921014974775910.1016/S0140-6736(18)31487-930191830 36.WawrzyniakAJRodrÃ­guezAEFalconAEChakrabartiAParraAParkJet al.The association of individual and" exact="systemic" post="barriers to optimal medical care in people living with"/>
 <result pre="systemic barriers to optimal medical care in people living with" exact="HIV/AIDS" post="(PLWHA) in Miami-Dade CountyJ Acquir Immune Defic Syndr2015691S63S7210.1097/QAI.000000000000057225867780"/>
</results>
